ESMO Guideline for Mantle Cell Lymphoma

An Expert Interview With Martin Dreyling, MD, PhD

Martin H. Dreyling, MD, PhD; Linda Brookes, MSc


September 25, 2014

In This Article

Where the Consensus Waivered

Medscape: Is there any mention of central nervous system (CNS) prophylaxis in the new guideline?

Prof Dreyling: With the introduction of cytarabine into the induction regimen, at least in younger patients, we think that CNS relapses will occur less often. We also refer to a recent publication, which summarizes our data,[23] and do not routinely recommend CNS prophylaxis in first-line therapy. We mention that it might only be considered in selected, high-risk cases with blastoid histology, elevated LDH, Eastern Cooperative Group (ECOG) performance status ≥ 2, and a high MIPI score.

Medscape: Were there any other points discussed where it was difficult to reach a consensus?

Prof Dreyling: There were a few points which are not really mentioned formally in the guidelines. For example, the use of positron emission tomography/computed tomography (PET/CT) is not mandatory, but it may be helpful for response evaluation specifically in limited-stage disease. Another point, which is somewhat new in guidelines, is our conclusion that in limited-stage MCL, radiation alone is not enough; we recommend chemotherapy plus radiation. The other recommendation that might help to advise our colleagues is the watch-and-wait approach in indolent cases.

Other aspects in the guideline are really modifications of prior recommendations. For example, in relapsed disease, we essentially recommend either bendamustine or high-dose cytarabine for relapsed patients, but in early relapse or early refractory cases, newer targeted approaches should be strongly considered.

Medscape: Are there any recommendations about new drugs that are in clinical trials?

Prof Dreyling: We only commented on drugs that are registered for use in MCL. However, we also listed data on the most promising investigational drugs, such as idelalisib,[24] ABT-199 (GDC-0199),[25] and obinutuzumab (GA-101),[26] but we purposely did not rank these agents on the strength of recommendations.

Medscape: In other words, the information is available if physicians are considering whether to recommend a patient to go on a clinical trial of a new drug?

Prof Dreyling: Absolutely. For example, we note that on the basis of published data, response rates of idelalisib are high in MCL[24] but response duration seems to be much shorter than with ibrutinib.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: